Clinical Trial

VLA1553-403 Pregnancy Surveillance Study

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-07-21
notable Trial sites expanded: 0 -> 3 locations 2026-07-21
Trial Details
NCT Number NCT07414524
Lead Sponsor Valneva Austria GmbH
Collaborators: Butantan Foundation, Coalition for Epidemic Preparedness Innovations
Conditions Chikungunya Virus Infection
Enrollment 200 participants
Start Date 2026-06-11
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20